Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, multicenter, randomized, parallel controlled study to compare the efficacy and safety profile of chemo-radiotherapy with concomitant HMPL-002 use compared to standard chemo-radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer

Next Previous
Search
Trial Profile

An open label, multicenter, randomized, parallel controlled study to compare the efficacy and safety profile of chemo-radiotherapy with concomitant HMPL-002 use compared to standard chemo-radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HMPL 002 (Primary) ; Antineoplastics
  • Indications Cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Hutchison MediPharma; HUTCHMED

    • Most Recent Events

    • 23 Feb 2009 New trial record.
    • 08 Feb 2009 Interim results data have been reported in a Chi-Med media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top